Rockefeller Capital Management
SYRE icon

Rockefeller Capital Management’s Spyre Therapeutics SYRE Stock Holding History

Rockefeller Capital Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.21M Sell
47,466
-16,536
-26% -$1.21M 0.01% 1047
2026
Q1 		$3.23M Buy
64,002
+63,453
+11,558% +$2.39M 0.01% 1095
2025
Q4 		$18K Buy
549
+148
+37% +$3.87K ﹤0.01% 3560
2025
Q3 		$6.72K Buy
+401
New +$6.54K ﹤0.01% 3785

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Rockefeller Capital Management's SYRE Position: Q2 2026 in Review

Rockefeller Capital Management reduced its Spyre Therapeutics (SYRE) stake by 26% in Q2 2026, selling an estimated $1.21M and leaving 47,466 shares worth $4.21M. The position accounts for 0.01% of the portfolio, ranked #1047.

Rockefeller Capital Management first reported a position in SYRE in Q3 2025 and has held it in 4 quarters since. 266 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Rockefeller Capital Management held 47,466 shares of Spyre Therapeutics worth $4.21M as of Q2 2026.
  • Rockefeller Capital Management sold 16,536 Spyre Therapeutics shares in Q2 2026, an estimated $1.21M.
  • Spyre Therapeutics made up 0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #1047 holding.
  • Rockefeller Capital Management first reported a position in Spyre Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 266 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.